NEWBORN SCREENING ONTARIO DÉPISTAGE NÉONATAL ONTARIO				Lab Use Only			
MOLECULAR REQUISITION							
SHIP SAMPLES TO: NSO SPECIMEN	-	1 0 1 1 0					
PATIENT INFORMATION	ad Ottawa, ON K1H	I OIVIO		ORDE	ERING PROVIDER		
Health Card Number				Name			
	□ Male □ Female	уууу	mm dd				
	□ Ambiguous □ Unk			Email	I		
Patient's Telephone Contact Number MRN/Hospital Number			Phone	e Fax			
Patient's Last Name Patient's First Name		nt's First Name	☐ Fetus of:	PHOH	е гах		
Tatients and tatie				Institu	ution		
Patient's Address				Copy results to clinician/practitioner: Name			
Ethnicity:				Phone	e Fax		
For STAT requests please indicate	how a shorter TAT	will change patien	t management:				
Ongoing pregnancy; result needed for decision making within 6wks (i.e. termination or birth) Estimated due date:				Copy results to clinician/practitioner:			
Positive newborn screens where			atment decisions	Phone	e Fax		
Expedited results will directly in For inquiries please contact <u>nsome</u>	-						
TEST REQUESTED see FAQ section	n on NSO website fo	or more information	1		SPECIMEN TYPE		
Targets of Newborn Screening – targeted panel (complete Section 1)				Whole Blood (room temp, EDTA tubes) Adult 2x5mL, Children 2x4mL, Infant ≤2yo 1x3mL			
Primary Immune Deficiencies –	augmented exome	Slice (complete Section	on 2; whole blood or DN	A) Umbilical Cord blood (maternal sample for MCC			
Mitochondrial Diseases – augm	ented exome slice (c	complete Section 3; w	hole blood or DNA)	studies required) EDTA blood DBS			
TREC (DBS only) cho	eck here if purines also	required		DNA (>10 μg with at least [50ng/ μL])			
SMA - ddPCR/MLPA				Source:			
CFTR common mutation panel (for carrier testing and	CF newborn screen po	sitive only)	DBS (Dried bloodspot - Whatman 903)			
Familial Variant Testing (complete table below)					Other:		
Maternal Cell Contamination (MCC) studies (for prenatal and umbilical cord blood testing)					Contact NSO prior to sending		
□ Variant reinterpretation (mus	t attach NSO report is:	sued >=1 year ago)		•			
SPECIMEN COLLECTION							
Date of collection (YYYY/MM/DD)			Time of Collection (2	24HR)			
# Tubes (if applicable)			Specimen ID	,			
Please contact us if this is a precious sample. For more information on precious samples and our sample retention policy, please visit our website.							
AUTHORISATION	•	·	·	•			
I certify that the patient and/or legal g including benefits, risks, possible resul family. I have answered this person's of	ts, limitations and pos	sible implications for	himself/herself and his/h		Signature of the ordering healthcare provider:		
TESTING FOR KNOWN FAM	ILIAL VARIANT(S) 🗆 Please pro	vide proband's report	or NSO	report number and family history		
Proband's Name / DOB:				Relatio	nship to Proband:		
Gene and Variant(s): Transcript (NM number) required if report no	ot attached						
Personal History: Asymptomat	_	ic:					
Family History:							
Name(s) and DOB of other submitt	ed family members	:					

v13.0 - November 2



MOLECULAR REQUISITION

SHIP SAMPLES TO: NSO SPECIMEN HUB

415 Smyth Road Ottawa, ON K1H 8M8

SECTION 1: MOLECULAR TESTING FOR DISEASES TARGETED BY NEWBORN SCREENING ONTARIO							
Dis	sease Targeted:						
Ge	Gene (or choose from list below); If a multi-gene panel is being requested, please indicate if you are suspicious of a specific qene(s):						
Cli	nical Indication:						
Far	Family History (please attach all relevant documents related to previous test results and clinical diagnosis):						
ΑN	INO ACID DISORDERS (requ	esting a panel is equivalent	to requesting all related subpanels)			
х	PANEL	x	SUBPANEL	GENES			
_	TANEE		Hypermethioninemia	ADK, AHCY, CBS, GNMT, MAT1A, SLC25A13			
	Homocystinuria		Hypomethioninemia	MTHFR, MTR, MTRR			
	Phenylketonuria		PAH Deficiency	PAH (sequencing + reflex MLPA as needed)			
	Pilellyiketollulla		Biopterin Deficiencies	DNAJC12, GCH1, PCBD1, PTS, QDPR, SPR (for PKU panel, PAH will be done with reflex to these genes)			
	Tyrosinemia		Elevated Succinylacetone	FAH, GSTZ1			
	Tyrosinemia		Elevated Tyrosine	HPD, TAT			
			High citrulline	ASS1, SLC25A13			
	Urea Cycle Diseases		High ASA	ASL			
_			Low citrulline	CPS1, NAGS, OTC			
			Other	ARG1, CA5A, GLUL, GLUD1, OAT, SLC7A7, SLC25A2, SLC25A15			
	Maple Syrup Urine Disea			BCKDHA, BCKDHB, DBT, DLD			
OR				t to requesting all related subpanels)			
х	PANEL	х	SUBPANEL	GENES			
	Multiple carboxylase		Biotinidase Deficiency	BTD			
	Deficiency		Other	CA5A, HLCS			
	Propionic /		PA	PCCA, PCCB			
	Methylmalonic acidemias		MMA	ACSF3, ALDH6A1, MCEE, MLYCD, MMAA, MMAB, MMUT, SUCLA2, SUCLG1			
	Isovaleric acidemia		MMA + Homocysteinemia	ABCD4, AMN, CBLIF, CD320, CUBN, HCFC1, LMBRD1, MMACHC, MMADHC, TCN1, TCN2 ACADSB, FLAD1, IVD			
	Glutaric aciduria Type 1			GCDH			
			e deficiency	ACAD8			
				ALDH5A1			
· · · ·			ACAT1				
	TTY ACID OXIDATION DI		·	uest ALL genes noted below			
x	PANEL		GENES	ACCUPATION TO THE DESIGNATION OF			
<u> </u>	Carnitine Uptake Deficier	ncv	SLC22A5				
				mutation and del/dup +/- reflex sequencing) Check here for direct to sequencing			
	LCHAD/MTP Deficiency						
	VLCAD Deficiency						
	MADD/Glutaric Aciduria						
	CPT2 Deficiency		CPT2				
	CACT Deficiency		SLC25A20	SLC25A20			
	CPT1 Deficiency						
	Other FAOD ACAA2, ACAD9, ACADL, ACADS, ECHS1, HADH						
CONGENITAL ADRENAL HYPERPLASIA (if both requested, CYP21A2 will be performed first and reflex to panel)							
	21-Hydroxylase Deficiency CYP21A2 (includes MLPA and long-range PCR analyses for CNVs and common rearrangements)						
GALACTOSEMIA							
	GALT Deficiency						
	Other GALK1, GALE, GALM, GLUT2 (SLC2A2)						



NEWBORN SCREENING O	NTARIO		Lab Use Only			
DÉPISTAGE NÉONATAL O	NTARIO					
MOLECULAR REQUISITION						
SHIP SAMPLES TO: NSO SPECIMEN HU 415 Smyth Road C	JB Ottawa, ON K1H 8N	M8				
SECTION 2: MOLECULAR TESTING FOR INBORN ERRORS OF IMMUNITY						
PANEL SELECTION						
☐ Severe Combined/Primary Imm	nune Deficiency (2	51 gene augmented exome slice	e), please visit our <u>w</u>	<u>ebsite</u> for full li	st of genes	
SUBPANELS ADA Deficiency (ADA) Chronic Granulomatous Disease (CYBA, CYBB, CYBC1, G6PD, NCF1*, NCF2, NCF4) [*limited coverage due to high homology with duplicated regions in genome; please note that this gene is not included in the full severe combined/primary immune deficiency panel] *Additional testing to ensure full coverage of NCF1 can only be requested if patient has had an abnormal neutrophil oxidative burst index						
☐ Aicardi-Goutières syndro	me (<i>ADAR, IFIH1, F</i>	RNASEH2A, RNASEH2B, RNASEI	H2C, SAMHD1, TREX	(1)		
CLINICAL DETAILS						
Please provide detailed information regarding patient's phenotype, age of onset of symptoms, previous tests completed, and family history: Age of onset: Family history: Other:						
CLASSIC PRESENTATIONS ☐ ADA deficiency ☐ Aicardi-Goutières syndrome ☐ Autoimmune lymphoproliferative syndrome ☐ Chronic granulomatous disease ☐ Common variable immunodeficiency ☐ Familial cold autoinflammatory syndrome		□ G6PD deficiency □ Hyper IgE syndrome — Autosomal Dominant □ Hyper IgE syndrome — Autosomal Recessive □ Mendelian susceptibility to mycobacterial disease □ Severe combined immunodeficiency □ Wiskott-Aldrich syndrome □ Other (indicate if you are suspicious of a specific gene):				
LABORATORY FEATURES ☐ Elevated inflammatory markers ☐ Anemia ☐ Neutropenia ☐ Lymphopenia ☐ Thrombocytopenia ☐ Eosinophilia	☐ Abnormal TREG☐ Low or absent	CD4+ T cell number CD8+ T cell number ell function		nemia unoglobulins: unoglobulins:	□ IgG □ IgA □ IgM □ IgE □ IgG □ IgA □ IgM □ IgE se to vaccine	
CLINICAL FEATURES						
RHEUMATOLOGICAL/IMMUNE DYSREGULATION Arthritis Granulomas Hepato/splenomegaly Lymphadenopathy Recurrent fevers Systemic lupus erythematosus Vasculitis		HEMATOLOGICAL ☐ Autoimmune cytopenia ☐ Bone marrow failure ☐ Evan's syndrome ☐ Hemophagocytic lymphohistiocytosis ☐ Lymphoma		GASTROINTESTINAL ☐ Chronic diarrhea ☐ Celiac disease ☐ Enteropathy ☐ Inflammatory bowel disease ☐ Perianal abscess/fistula ☐ Liver/biliary disease		
INFECTIONS ☐ Abscesses ☐ Candidiasis ☐ Epstein-Barr virus ☐ Mycobacterium tuberculosis ☐ Non-tuberculous mycobacteria ☐ Recurrent infections: ☐ bacterial ☐ Recurrent pneumonia ☐ Skin and/or connective tissue infecti	_	DERMATOLOGICAL Alopecia Bullous pemphigoid Dermatitis/eczema Psoriasis Urticaria Vitiligo Warts	PULMONARY ☐ Asthma ☐ Bronchiectasis ☐ Chronic obstru pulmonary dis ☐ Interstitial lun	uctive sease	OTHER Developmental delay Endocrinopathy Facial dysmorphisms Failure to thrive Hearing loss Microcephaly Short stature Unexplained weight loss	



NEWBORN SCREENING ONTARIO DÉPISTAGE NÉONATAL ONTARIO	Lab Use Only		
MOLECULAR REQUISITION			
SHIP SAMPLES TO: NSO SPECIMEN HUB 415 Smyth Road Ottawa, ON K1H 8M8			
SECTION 3: MOLECULAR TESTING FOR MITOCHONE Criteria for testing requires selections from at least one classic of the control	presentation OR at least	one pathologic/lab feature <u>OR</u> at	t least one biochemical feature
PANEL SELECTION			
□ Full Mitochondrial Nuclear Gene Panel (425 gene augme SUBPANELS □ Mitochondrial Encephalopathy / Leigh Disease (117 □ mtDNA Depletion and Deletion (19 genes) □ Progressive External Ophthalmoplegia (PEO) / Optic □ Pyruvate Dehydrogenase Complex Deficiency (16 Please contact laboratory to request another subse	7 genes) c Atrophy (77 genes) genes)		genes
CLINICAL DETAILS			
Please provide detailed information regarding patient's phenoty	pe, age of onset of symp	toms, previous tests completed,	, and family history:
CLASSIC PRESENTATIONS Alpers disease Chronic progressive external ophthalmoplegia (CPEO) Gentamicin-related sensorineural hearing loss Kearns-Sayre syndrome Leber's hereditary optic neuropathy (LHON) Leigh disease	 ☐ Mitochondrial neuro ☐ Multiple symmetric ☐ Myoclonic epilepsy ☐ Neuropathy, ataxia, ☐ Pearson syndrome ☐ Primary lactic acidos ☐ Sensory-ataxia, neuropathy 	o-gastro-intestinal encephalopm lipomatosis with ragged-red fibers (MERRF) and retinitis pigmentosa (NARP	o) Imoparesis (SANDO)
PATHOLOGIC/LABORATORY FEATURES ☐ Ragged red fibers: % ☐ COX-negative fibers: % ☐ Ultrastructurally abnormal mitochondria by electron microscopy ☐ Muscle biopsy consistent with mitochondriopathy (affix report)	BIOCHEMICAL FEATURES ☐ Persistent hyperalaninemia ☐ Persistent abnormal excretion of lactate, pyruvate of TCA intermediates in urine ☐ Evidence of mtDNA depletion or multiple mtDNA deletions (affix results) ☐ <30% activity of any RC complex in tissue or cell line ☐ Increased lactate pyruvate ratio (>25) in skin fibroblasts		
CLINICAL FEATURES			
CENTRAL NERVOUS SYSTEM (CNS) Developmental delay Regression Movement disorder Seizures Hemiplegic or complicated migraine Peripheral neuropathy Sensorineural hearing loss	HEART ☐ Arrhythmias ☐ Cardiomyopathy ☐ Conduction block EYES ☐ Optic atrophy ☐ Pigmentary retinopa	☐ Ataxia	
OTHER ☐ Clinical progression with stepwise exacerbation of symptoms ☐ Elevated alanine (PAA) ☐ Elevated 3-methylglutaconic acid (UOA) ☐ GI tract: pseudoobstruction ☐ GI tract: hepatopathy ☐ Lactic acidosis (in pop-acute illness setting)	☐ Proximal renal tubul☐ Sideroblastic anemia☐ Short stature (<2 SD☐ Type 2 diabetes mel☐ Unexplained failure	below normal) litus	

